Lisata Therapeutics reports $352M offering sold

Lisata Therapeutics, Inc. raised $352 million in a securities offering. The company, incorporated in Delaware, is involved in the healthcare industry. The offering was filed with the SEC under Rule 506(b).

Original reporting
Published Oct 2, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$LSTA
Neutral
high confidence
Mentioned
$LSTA
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LSTANeutralMed
01

Why it matters

The filing provides the first public details of the capital raise, which may affect share price through dilution and cash balance changes.

02

Market read

Primary disclosure of a sizable raise for a micro‑cap biotech; relevant for investors tracking dilution risk and cash runway.

03

What to watch

Potential strategic partnerships or pipeline milestones that could offset dilution risk.

Relevance 7/10Novelty 8/10Timing: post filing today

Background

Lisata Therapeutics, a Delaware‑incorporated biotech, submitted a Form D for an exempt offering of equity securities totaling $352 million.

Company-level read

Ticker impact

$LSTANeutralHigh confidence
Context

Lisata Therapeutics filed a Form D announcing a $352M exempt offering of equity securities.

Expected impact

likely pressure as the market prices in dilution from the $352M raise

Evidence & confidence

Primary SEC filing, first public disclosure of a large raise for a micro‑cap biotech.

Market effects

May signal increased financing activity in the biotech sector.

Limited to US biotech investors.

Low, as the company is micro‑cap and US‑listed.

Counterpoint

The raise could fund pivotal trials that boost long‑term valuation despite short‑term dilution.

Key entities

  • Lisata Therapeutics, Inc.

    Biotech firm raising $352M via exempt equity offering.

Related articles

$LSTAMedAI 8/10

Lisata subsidiary Marea Therapeutics reports up to 72% triglyceride reduction in Phase 2b trial

Lisata Therapeutics' subsidiary Marea reported that its experimental antibody MAR001 reduced triglycerides by up to 72.2% in a Phase 2b trial, meeting all objectives. The trial involved 235 adults with severe hypertriglyceridemia. MAR001 also reduced remnant cholesterol and showed a safety profile comparable to placebo. Marea has started Part B of the trial and is developing a longer-acting version, MAR005.

$LSTAMedAI 8/10

Marea Therapeutics doses first patient in MAR002 phase 2 trial

Lisata Therapeutics' (LSTA) subsidiary Marea Therapeutics dosed the first patient in a Phase 2 trial for MAR002, a treatment for acromegaly. The trial aims to enroll 72 participants, with primary endpoint measuring IGF-1 reduction after 10 weeks. MAR002 could offer less frequent dosing than current treatments. Lisata's valuation may be impacted by clinical milestones, according to InvestingPro.

$LSTALow

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.

$LSTAHighAI 8/10

Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and secured $225M in financing, diluting legacy shareholders to 2.39% ownership. The funds will support operations into 2028, covering clinical trials for severe hypertriglyceridemia and acromegaly. Success could attract partnerships or improve future financing terms, but risks include clinical trial failures and cash settlement obligations.